Assessing the Impact of Different Linker Technologies on Platform Analytical Methods Used in ADC Development - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Assessing the Impact of Different Linker Technologies on Platform Analytical Methods Used in ADC Development

12:30 pm - Wednesday 14th October 2026

Evaluating analytical methods used in bioconjugate process development to provide key attribute information
Assessing the impact of a number of newer linkers on those analytics to confirm continued method suitability

Speakers:

Nigel Smith

Nigel Smith

Head, Analytical Services

Sterling Pharma Solutions